Drug Approval | January 03, 2024
Alembic Pharmaceuticals received 8 USFDA approvals in Q3FY24
The company has received five final approvals
The company has received five final approvals
Furthering cell therapy ambition across oncology and autoimmune diseases
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Expanding to states like Maharashtra, Andhra Pradesh, Telangana, and Manipur while marking the significant milestone in its journey towards providing accessible healthcare services
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.
Lenalidomide capsules are a prescription medicine used in adults for the treatment of multiple myeloma.
The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules
Submissions based on favorable MagnetisMM-3 trial results in patients with relapsed or refractory multiple myeloma
Subscribe To Our Newsletter & Stay Updated
